Effect of Bisoprolol Versus Other Beta-Blockers on Glycemic Control and Metabolic Parameters in Type 2 Diabetes: A Retrospective Cohort Study.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Drugs and Therapy Pub Date : 2025-07-28 DOI:10.1007/s10557-025-07753-7

Sivan Gazit, Yogev Yonatan, Moshe Baruch Hoshen, Felix Mahfoud, Tal Tova Patalon

{"title":"Effect of Bisoprolol Versus Other Beta-Blockers on Glycemic Control and Metabolic Parameters in Type 2 Diabetes: A Retrospective Cohort Study.","authors":"Sivan Gazit, Yogev Yonatan, Moshe Baruch Hoshen, Felix Mahfoud, Tal Tova Patalon","doi":"10.1007/s10557-025-07753-7","DOIUrl":null,"url":null,"abstract":"Purpose: β-blockers (BB) are a heterogeneous class of medications guideline-recommended for heart failure (HF) and diabetes mellitus (DM). However, physicians may be reluctant to prescribe BBs due to concerns regarding negative metabolic effects. The primary objective was to assess the short-term change in glucose control in PwT2DM (patients with T2DM) who initiated bisoprolol versus the reference cohorts. Secondary objectives were to assess change in lipid control, and proportion of patients with hypoglycemic events during follow-up in PwT2DM who initiated bisoprolol.Methods: We performed a retrospective cohort study of T2DM patients on bisoprolol compared to no treatment, carvedilol, other selective BBs, or nonselective BBs. Anonymized data was collected from the Maccabi Health Services (MHS) database between 2003 and 2023.Results: A total of 12,981 records were analyzed. The reduction in HbA1C (difference of -0.05 [-0.09, -0.01]), fasting plasma glucose (FPG) (difference of -1.72 [-3.35, -0.1]), and cholesterol measures (total, HDL, LDL differences of -9.12 [-10.94, -7.31], -0.94 [-1.24, -0.65], and -7.89 [-9.53, -6.26], respectively) was significantly greater in the bisoprolol cohort compared to reference cohort 1 (no treatment). In cohort 2, the reduction in HbA1C was significantly greater with carvedilol users compared to bisoprolol users (difference of 0.34 [0.04, 0.63]). The reduction in total cholesterol and LDL was significantly greater in the bisoprolol cohort compared to reference cohort 4 (nonselective BB users, differences of -5.86 [-9.46, -2.25] and -7.08 [-10.25, -3.92], respectively).Conclusion: Bisoprolol had a neutral effect on the glycemic profile with a statistically beneficial impact on the lipid profile, comparable to carvedilol.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Drugs and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10557-025-07753-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: β-blockers (BB) are a heterogeneous class of medications guideline-recommended for heart failure (HF) and diabetes mellitus (DM). However, physicians may be reluctant to prescribe BBs due to concerns regarding negative metabolic effects. The primary objective was to assess the short-term change in glucose control in PwT2DM (patients with T2DM) who initiated bisoprolol versus the reference cohorts. Secondary objectives were to assess change in lipid control, and proportion of patients with hypoglycemic events during follow-up in PwT2DM who initiated bisoprolol.

Methods: We performed a retrospective cohort study of T2DM patients on bisoprolol compared to no treatment, carvedilol, other selective BBs, or nonselective BBs. Anonymized data was collected from the Maccabi Health Services (MHS) database between 2003 and 2023.

Results: A total of 12,981 records were analyzed. The reduction in HbA1C (difference of -0.05 [-0.09, -0.01]), fasting plasma glucose (FPG) (difference of -1.72 [-3.35, -0.1]), and cholesterol measures (total, HDL, LDL differences of -9.12 [-10.94, -7.31], -0.94 [-1.24, -0.65], and -7.89 [-9.53, -6.26], respectively) was significantly greater in the bisoprolol cohort compared to reference cohort 1 (no treatment). In cohort 2, the reduction in HbA1C was significantly greater with carvedilol users compared to bisoprolol users (difference of 0.34 [0.04, 0.63]). The reduction in total cholesterol and LDL was significantly greater in the bisoprolol cohort compared to reference cohort 4 (nonselective BB users, differences of -5.86 [-9.46, -2.25] and -7.08 [-10.25, -3.92], respectively).

Conclusion: Bisoprolol had a neutral effect on the glycemic profile with a statistically beneficial impact on the lipid profile, comparable to carvedilol.

查看原文本刊更多论文

比索洛尔与其他β受体阻滞剂对2型糖尿病血糖控制和代谢参数的影响：一项回顾性队列研究

目的：β受体阻滞剂（BB）是指南推荐用于心力衰竭（HF）和糖尿病（DM）的一类异质性药物。然而，由于担心对代谢的负面影响，医生可能不愿意开bb。主要目的是评估使用比索洛尔的PwT2DM （T2DM患者）与对照组的血糖控制的短期变化。次要目的是评估脂质控制的变化，以及PwT2DM患者在随访期间服用比索洛尔后出现低血糖事件的比例。方法：我们对接受比索洛尔治疗的T2DM患者与未接受治疗、卡维地洛、其他选择性BBs或非选择性BBs的患者进行了回顾性队列研究。2003年至2023年期间从马卡比卫生服务（MHS）数据库收集了匿名数据。结果：共分析12981份病历。比索洛尔组的HbA1C（差异为-0.05[-0.09,-0.01]）、空腹血糖（FPG）（差异为-1.72[-3.35,-0.1]）和胆固醇（总、高密度脂蛋白、低密度脂蛋白差异分别为-9.12[-10.94,-7.31]、-0.94[-1.24,-0.65]和-7.89[-9.53,-6.26]）的降低显著高于参考组1（未治疗）。在队列2中，卡维地洛患者的HbA1C降低明显大于比索洛尔患者（差异为0.34[0.04,0.63]）。与参考队列4相比，比索洛尔组总胆固醇和低密度脂蛋白的降低明显更大（非选择性BB使用者，差异分别为-5.86[-9.46,-2.25]和-7.08[-10.25,-3.92]）。结论：比索洛尔对血糖的影响是中性的，对血脂的影响在统计学上是有益的，与卡维地洛相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Drugs and Therapy 医学-心血管系统

CiteScore

8.30

自引率

0.00%

发文量

110

审稿时长

4.5 months

期刊介绍： Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.